Holen Sie sich die Stockscreener-App
1.73
4.22%
0.07
Handel nachbörslich:
1.73
Schlusskurs vom Vortag:
$1.66
Offen:
$1.66
24-Stunden-Volumen:
1.63M
Relative Volume:
0.76
Marktkapitalisierung:
$275.07M
Einnahmen:
$10.00M
Nettoeinkommen (Verlust:
$-29.47M
KGV:
-8.65
EPS:
-0.2
Netto-Cashflow:
$-21.55M
1W Leistung:
+8.81%
1M Leistung:
+7.45%
6M Leistung:
-39.93%
1J Leistung:
-53.99%
1-Tages-Spanne:
$1.6441
$1.78
1-Wochen-Bereich:
$1.47
$1.78
52-Wochen-Spanne:
$1.47
$5.02
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Firmenname
Mereo Biopharma Group Plc Adr
Sektor
Branche
Telefon
4403330237300
Adresse
ONE CAVENDISH PLACE, LONDON
Vergleichen Sie MREO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
1.73 | 263.94M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-27 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-13 | Fortgesetzt | BTIG Research | Buy |
| 2022-08-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-05 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Needham | Buy |
Alle ansehen
Mereo Biopharma Group Plc Adr Aktie (MREO) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - FinancialContent
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives Average Rating of “Buy” from Analysts - Defense World
Mereo BioPharma ADR earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK
Mereo's Setrusumab Phase 3 Trials Hit Key Safety Milestone: Year-End Results Coming for Rare Bone Disease - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Pomerantz LLP Investigates Mereo BioPharma Group Securities Fraud Claims. - AInvest
Pomerantz LLP investigates Mereo BioPharma Group securities fraud claims. - AInvest
Mereo BioPharma investigated for potential securities fraud. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Connect - ACCESS Newswire
Pomerantz LLP investigates Mereo BioPharma securities fraud claims. - AInvest
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Group plc (MREO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Investors in Mereo BioPharma Group plc (MREO) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
MREO ACTIVE INVESTIGATION: Lost Money on Mereo BioPharma Group plc? Contact Levi & Korsinsky Now - ACCESS Newswire
ATTENTION MREO Shareholders: Lost Money on Mereo BioPharma Group plc? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Investigation Opened on Behalf of Mereo BioPharma Group plc (MREO) ShareholdersContact Levi & Korsinsky - ACCESS Newswire
Ongoing Securities Investigation into Mereo BioPharma Group plc (MREO)Contact Levi & Korsinsky - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Stockholders to Connect - ACCESS Newswire
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Consensus Rating of “Buy” by Brokerages - Defense World
Investigation Underway: Mereo BioPharma Group plc (MREO)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
MREO ALERT: Ongoing Investigation Into Mereo BioPharma Group plcContact Levi & Korsinsky - ACCESS Newswire
Protect Your Investment: Contact Levi & Korsinsky About the Mereo BioPharma Group plc (MREO) Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
BTIG reiterates Buy rating on Mereo BioPharma stock amid trial progress By Investing.com - Investing.com South Africa
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.43% - Investing.com
United States shares higher at close of trade; Dow Jones Industrial Average up 0.43% - Investing.com India
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End - Yahoo Finance
JPMorgan maintains Mereo BioPharma stock rating despite trial setback By Investing.com - Investing.com India
JPMorgan maintains Mereo BioPharma stock rating despite trial setback - Investing.com
Mereo BioPharma and Ultragenyx advance Phase 3 Orbit study for osteogenesis imperfecta - Investing.com India
SEC Form N-CSRS filed by abrdn World Healthcare Fund Shares of Beneficial Interest - Quantisnow
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Mereo BioPharma Group plc SEC 10-Q Report - TradingView
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire
Mereo Biopharma Group Plc ADR (MREO) can make a big difference with a little luck - Sete News
Analyzing Mereo Biopharma Group Plc ADR (MREO) After Recent Trading Activity - knoxdaily.com
How should investors view Mereo Biopharma Group Plc ADR (MREO)? - uspostnews.com
Analytical Overview: Mereo Biopharma Group Plc ADR (MREO)’s Ratios Tell a Financial Story - DWinneX
Balance Sheet Insights: Halliburton Co (HAL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Finanzdaten der Mereo Biopharma Group Plc Adr-Aktie (MREO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):